CSIMarket
 


Avadel Pharmaceuticals Plc  (AVDL)
Other Ticker:  
 

Avadel Pharmaceuticals Plc's Quick Ratio

AVDL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 2.88 below Avadel Pharmaceuticals Plc average.

Within Major Pharmaceutical Preparations industry 272 other companies have achieved higher Quick Ratio than Avadel Pharmaceuticals Plc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 677 to 936.

Explain Quick Ratio?
How much Cash & cash equivalents AVDL´s has?
What are AVDL´s Current Liabilities?


AVDL Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 31.2 % 12 % 84.11 % 172.8 % 137.08 %
Y / Y Cash & cash equivalent Change 43.86 % 54.16 % -18.27 % -38.62 % -41.2 %
Quick Ratio MRQ 2.88 3.16 1.27 1.76 2.63
AVDL's Total Ranking # 936 # 677 # 510 # 1395 # 1229
Seq. Current Liabilities Change 4.77 % -36.09 % 44.73 % 35.39 % -10.57 %
Seq. Cash & cash equivalent Change -4.57 % 59.04 % 4.58 % -9.37 % 2.26 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 273
Healthcare Sector # 476
Overall Market # 936


Quick Ratio Statistics
High Average Low
23.73 3.7 0.17
(Mar 31 2021)   (Dec 31 2013)




Financial Statements
Avadel Pharmaceuticals Plc's Current Liabilities $ 53 Millions Visit AVDL's Balance sheet
Avadel Pharmaceuticals Plc's Cash & cash equivalent $ 153 Millions Visit AVDL's Balance sheet
Source of AVDL's Sales Visit AVDL's Sales by Geography


Cumulative Avadel Pharmaceuticals Plc's Quick Ratio

AVDL's Quick Ratio for the trailling 12 Months

AVDL Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 31.2 % 12 % 84.11 % 172.8 % 137.08 %
Y / Y Cash & cash equivalent TTM Growth 43.86 % 54.16 % -18.27 % -38.62 % -41.2 %
Quick Ratio TTM 2.15 2.06 1.85 2.34 3.3
Total Ranking TTM # 927 # 1036 # 1207 # 1243 # 1028
Seq. Current Liabilities TTM Growth 4.77 % -36.09 % 44.73 % 35.39 % -10.57 %
Seq. Cash & cash equivalent TTM Growth -4.57 % 59.04 % 4.58 % -9.37 % 2.26 %


On the trailing twelve months basis AVDL Cash & cash equivalent soared by 43.86 % in III Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in Avadel Pharmaceuticals Plc's Quick Ratio to 2.15, Quick Ratio remained below AVDL average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 489 other companies have achieved higher Quick Ratio than Avadel Pharmaceuticals Plc. While Quick Ratio overall ranking has improved so far to 629, from total ranking during the twelve months ending second quarter 2023 at 2431.

Explain Quick Ratio?
How much Cash & cash equivalents AVDL´s has?
What are AVDL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 490
Healthcare Sector # 1002
Within the Market # 936


trailing twelve months Quick Ratio Statistics
High Average Low
13.95 5.34 1.83
(Sep 30 2021)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Amylyx Pharmaceuticals Inc   7.78 $ 355.045  Millions$ 45.617  Millions
Gossamer Bio Inc   7.77 $ 328.888  Millions$ 42.316  Millions
Glycomimetics Inc   7.74 $ 49.460  Millions$ 6.391  Millions
Leap Therapeutics inc   7.57 $ 80.743  Millions$ 10.669  Millions
Hoth Therapeutics Inc   7.51 $ 11.853  Millions$ 1.579  Millions
Applied Molecular Transport Inc   7.47 $ 18.103  Millions$ 2.422  Millions
Aileron Therapeutics Inc   7.43 $ 12.069  Millions$ 1.624  Millions
Ngm Biopharmaceuticals Inc   7.43 $ 166.045  Millions$ 22.345  Millions
Verrica Pharmaceuticals Inc   7.41 $ 84.308  Millions$ 11.374  Millions
Nanoviricides inc   7.35 $ 6.970  Millions$ 0.948  Millions
Kronos Bio Inc   7.27 $ 186.713  Millions$ 25.672  Millions
Carisma Therapeutics Inc   7.27 $ 94.137  Millions$ 12.951  Millions
Vera Therapeutics Inc   7.24 $ 159.939  Millions$ 22.103  Millions
Dermata Therapeutics Inc   7.23 $ 6.631  Millions$ 0.917  Millions
Shattuck Labs Inc   7.19 $ 101.074  Millions$ 14.059  Millions
Nektar Therapeutics  7.15 $ 372.658  Millions$ 52.112  Millions
Abcellera Biologics Inc   7.13 $ 785.840  Millions$ 110.239  Millions
Lumos Pharma Inc   7.13 $ 42.694  Millions$ 5.990  Millions
Mirati Therapeutics Inc   7.11 $ 976.434  Millions$ 137.379  Millions
Verastem inc   6.96 $ 165.663  Millions$ 23.812  Millions
Sage Therapeutics Inc   6.95 $ 876.052  Millions$ 126.037  Millions
Immix Biopharma Inc   6.93 $ 19.582  Millions$ 2.826  Millions
Rain Oncology Inc   6.93 $ 77.320  Millions$ 11.163  Millions
Lexicon Pharmaceuticals Inc   6.77 $ 218.427  Millions$ 32.261  Millions
Mira Pharmaceuticals Inc   6.76 $ 5.868  Millions$ 0.868  Millions
Zai Lab Limited  6.57 $ 820.406  Millions$ 124.896  Millions
Assembly Biosciences Inc   6.48 $ 46.210  Millions$ 7.132  Millions
Abeona Therapeutics Inc   6.39 $ 53.754  Millions$ 8.412  Millions
Bolt Biotherapeutics Inc   6.38 $ 119.724  Millions$ 18.751  Millions
Mineralys Therapeutics Inc   6.37 $ 86.300  Millions$ 13.543  Millions

Date modified: 2023-11-10T00:07:31+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com